Navigation Links
Newly identified antibodies may improve pneumonia vaccine design
Date:9/22/2011

September 22, 2011 -- (Bronx, NY) -- Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria. The findings, which could improve vaccines against pneumonia, appear in the September/October issue of mBio, the online journal of the American Society for Microbiology.

Until recently, scientists thought that antibodies work against pneumococcal bacteria by killing them with the help of immune cells. However, several years ago, Einstein researchers discovered antibodies that were very effective against experimental pneumococcal disease in mice even though they were not able to induce bacterial killing by immune cells. In the current study, the researchers examined how these antibodies interact with pneumococcal bacteria and found that they cause the bacteria to clump together, enhancing a phenomenon called quorum sensing.

"Quorum sensing is a way that bacteria communicate with one another," explained senior author Liise-anne Pirofski, M.D., professor of (http://www.einstein.yu.edu/medicine/medicine.aspx) medicine and of microbiology & immunology, chief of infectious diseases at Einstein and Montefiore Medical Center, the University Hospital for Einstein, and the Selma and Dr. Jacques Mitrani Professor in Biomedical Research at Einstein. "Here, the ability of antibodies to enhance quorum sensing causes the bacteria to express genes that could kill some of their siblings, something called fratricide, and weaken the defense mechanisms that enable bacteria to survive and grow in a hostile environment."

The National Foundation for Infectious Diseases estimates that 175,000 people are hospitalized with pneumococcal pneumonia in the United States each year. In addition, pneumococcal bacteria cause 34,500 bloodstream infections and 2,200 cases of meningitis annually.

There are two pneumococcal vaccines: one for adults and one for infants and children. The pediatric pneumococcal conjugate vaccine has dramatically reduced the incidence of pneumococcal disease in children and adults by protecting vaccinated children and by reducing person-to-person transmission of the bacterium, (a phenomenon known as herd protection). However, the vaccine doesn't cover all strains of disease-causing pneumococcus, and the vaccine currently used for adults does not prevent pneumonia. Fortifying current pneumococcal vaccines to stimulate antibodies that make pneumococcal bacteria less able to protect themselves -- or kill them directly -- could enhance their effectiveness.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Newly-discovered mechanism can explain the Beckwith-Wiedemann syndrome
2. Newly identified gene powerful predictor of colon cancer metastasis
3. Newly found enzymes may play early role in cancer
4. Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect
5. UC Davis research shows that newly discovered drug reduces heart enlargement
6. Newly described contaminant sources in Katrina-flooded homes pose health risks
7. DNA evidence is in, newly discovered species of fish dubbed H. psychedelica
8. Newly discovered gene plays vital role in cancer
9. Newly discovered epidermal growth factor receptor active in human pancreatic cancers
10. Newly discovered reactions from an old drug may lead to new antibiotics
11. Newly discovered snow roots are evolutionary phenomenon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... The impressively ... focus of researchers, engineers, product developers, and industry suppliers gathered last week for ... SPIE, the international society for optics and photonics , the event drew ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging bio and technology start-ups, is hosting “Celebration Friday” ... This double event will start with libations and networking at 3:30 p.m. at ...
(Date:4/20/2017)... Ca (PRWEB) , ... April 20, 2017 , ... ... Virtual Event , this new webinar will explore challenging patient cases when screening ... to the hospital, there may be a need for bridging parental anticoagulation especially ...
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and ... 2 data evaluating galcanezumab for the prevention of migraine ... which will take place April 22-28, 2017, in ... present four abstracts at AAN, including safety and patient ... factors associated with a reduction in monthly migraine headache ...
Breaking Biology Technology: